The Cancer Letter

Inside information on cancer research and drug development

Vol.
35
No.
1
January 27, 2012Jan 27, 2012
Free
DOWNLOAD THE PDF

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

ETP-ALL May Be Linked To Acute Myeloid Leukemia

CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup

BRCA1 and BRCA2 Mutations Linked To Higher Survival

Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease

Chromosomal Abnormalities Predict Long Median Survival

Analysis Shows No Mortality Benefit From Regular PSA Screening

Ovarian Cancer Symptom Indices May Need to be Re-Evaluated

Self-Collected Pap Smear Tests Could Advance HPV Screening

Trials Approved by NCI CTEP For the Month of January

Palmetto Establishes Coverage For Thyroid Genomic Test

FDA Approves Inlyta Pill For Renal Cell Carcinoma

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account